Perrigo (PRGO) Income from Continuing Operations (2012 - 2026)
Perrigo's (PRGO) quarterly Income from Continuing Operations came in at 389800000.0 in Q1 2026, down 389900.0% year-on-year from N/an in Q1 2025, and up 72.44% on a QoQ basis from 1414600000.0 in Q4 2025.
Perrigo (PRGO) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Perrigo (PRGO) has 15 years of Income from Continuing Operations data on file, last reported at 389800000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 389900.0% year-over-year to 389800000.0 in Q1 2026; TTM through Mar 2026 was 1792200000.0, a 988.16% decrease from a year earlier, with the FY2025 full-year figure at 1402300000.0, down 772.62% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 389800000.0, up from 1414600000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for PRGO reached as high as 15400000.0 in Q3 2023 and fell as low as 1414600000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 122841176.47 across 5 years, with a median of 12700000.0 in 2022.
- Across the five-year window, Income from Continuing Operations soared 472.73% in 2024 and sank 389900.0% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 12700000.0 in 2022, then plunged by 118.11% to 27700000.0 in 2023, then plunged by 49.82% to 41500000.0 in 2024, then sank by 3308.67% to 1414600000.0 in 2025, then surged by 72.44% to 389800000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 389800000.0 in Q1 2026, 1414600000.0 in Q4 2025, and 12700000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.04 Bn | 325.50 Mn | -389.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -389.80 Mn |
| Dec 31, 2025 | -1.41 Bn |
| Sep 27, 2025 | 12.70 Mn |
| Jun 28, 2025 | -500,000.00 |
| Mar 29, 2025 | 100,000.00 |
| Dec 31, 2024 | -41.50 Mn |
| Sep 28, 2024 | -17.60 Mn |
| Jun 29, 2024 | -105.70 Mn |
| Mar 30, 2024 | 4.10 Mn |
| Dec 31, 2023 | -27.70 Mn |
| Sep 30, 2023 | 15.40 Mn |
| Jul 1, 2023 | 8.90 Mn |
| Apr 1, 2023 | -1.10 Mn |
| Dec 31, 2022 | -12.70 Mn |
| Oct 1, 2022 | -52.10 Mn |
| Jul 2, 2022 | -64.90 Mn |
| Apr 2, 2022 | -1.30 Mn |
| Dec 31, 2021 | 32.10 Mn |
| Oct 2, 2021 | -53.90 Mn |
| Jul 3, 2021 | -111.90 Mn |